Vitamin D Deficiency: Classification and Management

Physiology Background

Classification by Serum 25(OH)D Level

• Levels < 37 nmol/L (< 15 ng/mL) are associated with rising PTH and falling bone density (Harrison's 22e)
• The National Academy of Medicine defines sufficiency as > 50 nmol/L (> 20 ng/mL)
• Circulating 25(OH)D < 8 ng/mL is highly predictive of histological osteomalacia (Goodman & Gilman)
• Note: 1,25(OH)2D should NOT be used to diagnose vitamin D deficiency in patients with normal renal function, as it is often paradoxically normal even in severe deficiency due to secondary hyperparathyroidism driving the 1α-hydroxylase (Harrison's 22e)

Causes of Vitamin D Deficiency

• Reduced sunlight exposure (elderly, institutionalized, dark skin, high latitudes, sunscreen use, cultural clothing)
• Dietary absence or malabsorption

• Drugs that induce hepatic CYP450 enzymes: barbiturates, phenytoin, rifampin
• Gain-of-function CYP3A4 mutations (autosomal recessive)
• Impaired enterohepatic circulation (terminal ileal disease, nephrotic syndrome - urinary loss)

• Severe liver disease
• Isoniazid
• 25-hydroxylase gene mutations (rare)

• Chronic kidney disease (most common cause of impaired activation)
• Hypoparathyroidism
• Oncogenic osteomalacia / FGF23 excess
• X-linked hypophosphatemic rickets
• Fibrous dysplasia
• Ketoconazole
• 1α-Hydroxylase mutations (Vitamin D-dependent rickets type I / PDDR)

• VDR mutations (Hereditary Vitamin D-Resistant Rickets / VDDR type II) - characterized by rickets, hypocalcemia, and total alopecia
• Phenytoin (also impairs end-organ response)

• Obesity (adipose sequestration of vitamin D)
• Gastric bypass / short gut syndrome
• Inflammatory bowel disease, pancreatic insufficiency (malabsorption)

Clinical Manifestations

Mild to Moderate Deficiency

• Often asymptomatic
• Subtle secondary hyperparathyroidism
• Reduced bone mineral density

Severe / Longstanding Deficiency

• Hypocalcemia + secondary hyperparathyroidism
• Osteomalacia (adults): impaired bone matrix mineralization → pseudofractures (Looser's zones) at scapula, pelvis, femoral neck; prone to pathological fractures and bowing of weight-bearing bones
• Rickets (children, before epiphyseal fusion): widened growth plate, rachitic rosary at costochondral junctions, bowing of long bones, delayed calvarial suture closure
• Proximal myopathy: striking feature of severe deficiency - rapid resolution with treatment
• Increased overall and cardiovascular mortality (association)
• Acute symptomatic hypocalcemia (numbness, tetany, seizures) is uncommon unless there is concurrent hypomagnesemia or potent bisphosphonate use

Diagnosis

Management

General Principles (Harrison's 22e, Goodman & Gilman)

• Treatment should be directed at the underlying cause
• Always replete vitamin D together with calcium supplementation, since most consequences result from impaired mineral ion homeostasis
• Tailor dose to severity
• For patients with impaired 1α-hydroxylation (CKD, VDDR type I), use metabolites that bypass that step (calcitriol or alfacalcidol)
• Prefer daily dosing over large intermittent boluses in adults > 50 years - large bolus doses can paradoxically increase fractures and falls (VITAL trial data, Harrison's 22e)

Treatment Protocols by Age Group (Endocrine Society 2011 / Medscape)

• 2,000 IU/day of vitamin D2 or D3 for 6 weeks, OR
• 50,000 IU weekly for 6 weeks
• Then maintenance: 400-1,000 IU/day once 25(OH)D > 30 ng/mL

• 2,000 IU/day or 50,000 IU weekly for at least 6 weeks
• Then maintenance: 600-1,000 IU/day

• Repletion: 50,000 IU of vitamin D2 or D3 weekly for 3-12 weeks (pharmacologic repletion)
• Then maintenance: 800 IU/day (or 1,500-2,000 IU/day in higher-risk groups)
• In patients on enzyme-inducing drugs (barbiturates, phenytoin, rifampin): higher pharmacologic doses may be required for maintenance

• Age 1-70 years: 600 IU/day
• Age > 70 years: 800 IU/day

• Empiric supplementation beyond RDI is supported only for: ages 1-18, age > 75, pregnancy, and high-risk prediabetes
• Routine screening and supplementation in healthy adults is NOT recommended by 2024 guidelines

Special Situations

Monitoring

• Recheck serum 25(OH)D 3 months after initiating repletion
• Target: > 20 ng/mL (NAM) or > 30 ng/mL (clinical practice target per Endocrine Society 2011)
• Safety: toxicity is rare at doses < 10,000 IU/day; frank toxicity usually only at > 40,000 IU/day chronically

Vitamin D Toxicity (Hypervitaminosis D)

• Caused by excessive supplementation (not sun exposure - skin feedback limits cutaneous synthesis)
• Manifestations: hypercalcemia, hypercalciuria, nephrolithiasis, nephrocalcinosis, weakness, nausea
• Treatment: stop vitamin D and calcium, hydration, glucocorticoids in severe cases

Management of Tuberculosis (TB)

Overview

1. Latent TB Infection (LTBI) - infected but no active disease; treatment prevents reactivation
2. Active TB Disease - further split into drug-susceptible (DS-TB), drug-resistant (DR-TB), and extrapulmonary TB

Part 1 - Active Drug-Susceptible TB (DS-TB)

Principles of Treatment

• Combination therapy is mandatory - monotherapy rapidly selects resistant mutants
• Two phases: Intensive phase (kills actively replicating bacilli) + Continuation phase (eliminates persistent/dormant organisms)
• Directly Observed Therapy (DOT) is the standard of care, especially for intermittent regimens
• Always modify therapy once drug susceptibility testing (DST) results are available
• Daily regimens are preferred over intermittent ones (lower relapse risk, less resistance)

Standard 6-Month Regimen (Preferred - DS Pulmonary TB)

Newer 4-Month Regimen (WHO/ATS 2024 - Selected Patients)

• Non-inferior to 6-month regimen for drug-susceptible pulmonary TB in patients ≥ 12 years and ≥ 40 kg
• Moxifloxacin replaces ethambutol; rifapentine replaces rifampin
• NOT for: drug-resistant TB, most extrapulmonary TB, severe/complicated TB, pregnancy (relative caution), children < 12 years (standard 6-month preferred)
• This is a selective option, not a universal replacement for 2HRZE/4HR

Alternative 6-Month Dosing Schedules (CDC - in order of preference)

First-Line Drug Doses (Adults)

Always give pyridoxine (Vitamin B6) 25-50 mg/day with isoniazid to prevent peripheral neuropathy, especially in high-risk groups (elderly, malnourished, diabetics, HIV, alcoholics, pregnancy).

Prolonged Therapy Indications (beyond 6 months)

• HIV co-infection
• Cavitary pulmonary TB with positive sputum culture at 2 months
• Extrapulmonary TB: disseminated, CNS/meningeal (9-12 months), skeletal, pericardial
• Drug-resistant TB

Part 2 - Latent TB Infection (LTBI)

Who to Treat

• Recent TST/IGRA conversion
• Close contacts of active TB cases
• HIV-infected individuals (all TST/IGRA positives)
• Immunocompromised patients (on TNF inhibitors, transplant, corticosteroids)
• Immigrants from high-burden countries
• Healthcare workers with positive test

Active TB must be excluded before treating LTBI (history, exam, CXR, sputum if indicated).

LTBI Treatment Regimens (CDC-Approved)

• 3HP (INH + rifapentine weekly × 3 months) is the currently preferred short-course regimen
• 9 months of daily INH is preferred for pregnant women with high reactivation risk
• Twice-weekly INH regimens must be DOT
• 1HP (1-month daily INH + rifapentine): approved for HIV-infected adults ≥ 13 years; superior completion rates (~97% vs. 90%)

LTBI Monitoring

• Baseline LFTs not routinely required for all patients
• Baseline LFTs indicated for: liver disease, chronic alcohol use, HIV, pregnancy/postpartum < 3 months, risk factors for liver disease
• Stop treatment if: AST/ALT ≥ 5× ULN (asymptomatic) OR ≥ 3× ULN (with symptoms)

Part 3 - Drug-Resistant TB

Classification

MDR/RR-TB Treatment: BPaLM Regimen (ATS/CDC/ERS/IDSA 2024 - 2025 Guideline)

• BPaL (without moxifloxacin) is an alternative when fluoroquinolone is intolerant
• The 2024 guideline replaced older 15-18 month regimens with this 6-month all-oral regimen
• Strong recommendation based on TB-PRACTECAL and ZeNix trial data
• Linezolid TDM: target trough < 2 μg/mL to minimize toxicity (peripheral neuropathy, myelosuppression)
• Monitor for QTc prolongation (bedaquiline, moxifloxacin are both QTc-prolonging)
• DOT + close monitoring remains standard of care for BPaLM

Older Second-Line Agents (when newer regimens not available)

Part 4 - Special Situations

TB in HIV

• All HIV-positive patients with active TB must be treated
• Start anti-TB treatment first, then initiate ART within 2-8 weeks (except TB meningitis - delay ART 8 weeks due to IRIS risk)
• Use rifabutin instead of rifampin in patients on protease inhibitors (rifampin is a strong CYP3A4 inducer)
• Duration: at least 6 months (same as HIV-negative if drug-susceptible)
• Beware IRIS (Immune Reconstitution Inflammatory Syndrome): fever, worsening symptoms 2-8 weeks after ART initiation; distinguish from treatment failure; manage with NSAIDs or corticosteroids
• CD4 < 50: highest IRIS risk

TB in Pregnancy

• Active TB in pregnancy must be treated - risk to mother and fetus outweighs drug risks
• Safe drugs in pregnancy: Isoniazid, rifampin, ethambutol (first-line combination acceptable)
• Pyrazinamide: WHO recommends its use; some guidelines limit it (check local policy)
• Avoid: Streptomycin (ototoxicity to fetus), fluoroquinolones, most second-line agents
• Always give pyridoxine with isoniazid
• LTBI treatment: 9H (INH for 9 months) preferred if high reactivation risk; delay treatment until after first trimester if lower risk

TB Meningitis

• Treat with 2HRZE / 10HR (total 12 months)
• Add dexamethasone (0.4 mg/kg/day tapering over 6-8 weeks) - reduces mortality and disability
• Per 2026 Lancet Infectious Diseases practice guideline for tuberculous meningitis
• Delay ART at least 8 weeks in HIV co-infection to reduce IRIS risk

Pericardial TB

• Treat with standard 6-month regimen
• Adjunctive corticosteroids (prednisolone) are recommended to reduce risk of constrictive pericarditis

Pediatric TB (Children < 16 years)

• Nonsevere TB (no MDR suspicion): 4-month regimen 2HRZ(E)/2HR is now strongly recommended over 6-month regimen per ATS/CDC/ERS/IDSA 2025 guideline
• Severe or disseminated/meningeal TB: 6-12 months
• Weight-based dosing essential; adjust frequently as children grow

TB on Biologics / TNF Inhibitors

• Screen all candidates with TST/IGRA before starting anti-TNF therapy
• Treat LTBI before initiating biologics
• Active TB: stop biologic, start anti-TB treatment

Part 5 - Monitoring During Treatment

Part 6 - Key Drug Interactions

Summary Algorithm

Active TB Suspected
       ↓
Send: AFB smear + culture, DST, CXR
       ↓
Drug-Susceptible TB?
   ↓ YES                        ↓ NO (Resistant)
2HRZE / 4HR                  ↓
(6-month standard)      MDR/RR-TB → BPaLM × 26 weeks
 OR 2HPZM/2HPM           XDR-TB → BPaL ± clofazimine
(4-month if eligible)    Specialist referral essential
       ↓
Special circumstances?
HIV → add ART, use rifabutin with PIs
Pregnancy → avoid aminoglycosides/FQ
Meningitis → add dexamethasone, extend to 12 months
Pericardium → add steroids
       ↓
DOT + Monthly Monitoring + Adherence Support